Ascletis Pharma, Inc. 1672

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial with ASC50 in mild-to-moderate plaque psoriasis patients in the U.S. The objectives of the Phase I study were to evaluate the safety, efficacy and pharmacokinetics of once-daily 200 mg of ASC50 after 28-day treatment in mild-to-moderate plaque psoriasis patients (NCT07024602).

The acne vulgaris market is expected to progress steadily, supported by an increasing number of emerging therapies advancing through clinical development. Key players, including Ascletis Pharma and Sagimet Biosciences with Denifanstat (ASC40), and AOB Pharma with B244, are demonstrating a strong commitment to addressing unmet needs in acne treatment through continued efforts to develop innovative therapeutic options.New York, USA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Acne Vulgaris Market Set for S

FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, September 30, 2026, at 1:00 PM ET featuring Julie Harper, MD, Founding Director and past President of the American Acne and Rosacea Society. To register, click here. Dr. Harper will jo

Ascletis Pharma (SEHK:1672) has begun a U.S. Phase I trial of ASC36 oral tablets for obesity treatment after receiving FDA Investigational New Drug clearance, drawing renewed attention to its obesity pipeline. The FDA clearance and ASC36 Phase I launch arrive after a choppy run for Ascletis Pharma, with the share price up 10.13% over the past day to HK$8.97 but down 22.14% year to date, while the 3-year total shareholder return of 387.50% points to powerful longer term momentum that recent...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it has initiated a U.S. Phase I study of ASC36 oral tablets (oral amylin receptor peptide agonist) for the treatment of obesity after recently receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong Limited (the "HK Stock Exchange"), have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect (collectively, the "Hong Kong Stock Connect") programs, both with effect from September 7, 2026, pursuant to the announcements issued by the Shanghai Stock Exchange and th

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that the first participant has been dosed in a global Phase III clinical program of ASC30 for chronic weight management. ASC30 is an investigational, proprietary once-daily oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist being developed for chronic weight management and diabetes.

Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that following the Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA), it has initiated two Phase I studies in the U.S. for the treatment of obesity: ASC36, a once-monthly to once-quarterly next-generation amylin receptor peptide agonist and ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and GLP-1R/GIPR peptide agonist ASC35.

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces once-daily oral small molecule GLP-1 (ASC30) has received Phase III clearance from the U.S. Food and Drug Administration (FDA). ASC30 is the primary pillar of Ascletis' oral small molecule obesity portfolio. The Company has initiated a global Phase III program for ASC30 chronic weight management indication consisting of two pivotal global Phase III, multicenter, randomized, double-blind, placebo-controlled trials (AURORA-1 NCT07743463 and A

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ASC37, a next-generation GLP-1R/GIPR/GCGR[1] triple peptide agonist, demonstrated superior weight loss to tirzepatide in a diet-induced obese (DIO) mouse model. Following 11-day administration of ASC37 and tirzepatide at the same dose of 1 nmol/kg in DIO mice, ASC37 had statistically significant 88% greater relative body weight reduction compared to tirzepatide (Table 1). Furthermore, ASC37 demonstrated up to 41.5% weight loss in a dos